Literature DB >> 1730522

Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells.

P G Coulie1, M Somville, F Lehmann, P Hainaut, F Brasseur, R Devos, T Boon.   

Abstract

Limiting numbers of peripheral-blood mononuclear cells (PBMC) from melanoma patients were stimulated with irradiated autologous tumor cells in the presence of interleukins-2 and -4 and in the absence of feeder cells. The responder cells were restimulated every week. After 2 to 4 weeks, the microcultures were tested for their lytic activity against the autologous tumor cells. Significant lysis of the tumor cells was observed with a fraction of these microcultures, whereas no lysis was observed with control microcultures seeded without stimulator melanoma cells. Because our aim was to measure the precursor frequency of CTL showing specificity for the tumor, and not that of NK-like effectors that were also capable of lysing the melanoma cells, we used cold-target inhibition with an excess of NK target K562 to inhibit the NK-like activity. Microcultures whose lysis on the tumor cells was not abolished by K562 competition were observed. The specificity of these CTL clones was confirmed by the absence of lytic activity on autologous T-cell blasts. The numbers of microcultures with anti-tumor CTL activity fitted the zero-order of the Poisson distribution equation, indicating that they resulted from the activity of single T-cell clones. The frequency of anti-tumor CTL precursor cells (CTL-P) of 7 melanoma patients ranged from 1/900 to 1/33,000. Frequencies of anti-tumoral CTL-P were higher and NK-like effectors were less frequent when sorted CD8+ T lymphocytes were used as responder cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730522     DOI: 10.1002/ijc.2910500220

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

1.  Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC).

Authors:  K J Palmer; M Harries; M E Gore; M K Collins
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

2.  Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond.

Authors:  T F Gajewski
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

Review 3.  Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy.

Authors:  T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

Review 4.  New methods for assessing T-cell responses.

Authors:  N Bercovici; M T Duffour; S Agrawal; M Salcedo; J P Abastado
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

5.  In vivo selective expansion of a tumour-specific cytotoxic T-cell clone derived from peripheral blood of a melanoma patient after vaccination with gene-modified autologous tumour cells.

Authors:  Y Sun; P Möller; C Berking; E M Schlüpen; M Volkenandt; D Schadendorf
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

6.  Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.

Authors:  T Asai; W J Storkus; T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

Review 7.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

Review 8.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

9.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

10.  Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.

Authors:  Cedrik Michael Britten; Sylvia Janetzki; Leah Ben-Porat; Timothy M Clay; Michael Kalos; Holden Maecker; Kunle Odunsi; Michael Pride; Lloyd Old; Axel Hoos; Pedro Romero
Journal:  Cancer Immunol Immunother       Date:  2009-03-04       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.